- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Combination of CTLA-4 and PD-1 blockers for treatment of cancer ; volume:38 ; number:1 ; day:13 ; month:6 ; year:2019 ; pages:1-12 ; date:12.2019
Journal of experimental & clinical cancer research ; 38, Heft 1 (13.6.2019), 1-12, 12.2019
- Creator
-
Rotte, Anand
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-019-1259-z
- URN
-
urn:nbn:de:101:1-2019112605583710163036
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rotte, Anand
- SpringerLink (Online service)
Other Objects (12)
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways